English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: We investigated the incidence of long-term adverse events (AEs)/co-morbidities in early RA patients who had been treated additionally with prednisone 10 mg/day or placebo. Methods: In the Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA) II trial patients initiated treatment with MTX with 10 mg/day prednisone or placebo, given for 2 years. After the 2 year trial, patients were followed according to a protocol in clinical care. The occurrence of adverse events (AEs)/co-morbidities and the use of prednisone (it was the strategy to taper and stop it) was collected retrospectively from the medical charts. The incidence of long-term AEs/co-morbidities in the prednisone group was tested vs that in the former placebo group using Fisher’s exact tests. Results: Of the 236 patients included in the CAMERA II trial, follow-up data were available for 218 patients: prednisone, N 1⁄4 107; placebo, N 1⁄4 111; no longer followed according to protocol, N 1⁄4 18. The median follow-up time after the end of the 2-year trial period was 6 (range 0–9) and 6 (0–11) years, respectively. Eighty-six (80%) patients treated with prednisone could discontinue prednisone a median of 9 months after the end of the trial. The percentage of patients with AEs/co-morbidities is shown in Table 1. No statistically significant differences between the two groups were found. Conclusion: Of patients in the prednisone group during CAMERA II, 80% could discontinue prednisone after the trial. There was no increased incidence of long-term AEs/co-morbidities in the former prednisone group. Disclosure statement: The authors have declared no conflicts of interest. i98 Tuesday 26 April 2016 POSTER VIEWING I

rheumatology

089 Co-Morbidities after Daily Concomitant Treatment with 10 Mg Prednisone or Placebo in the 2 Year Computer-Assisted Management in Early Rheumatoid Arthritis Trial II